Performance and Predictive Value of First Trimester Screening Markers for Down Syndrome in Iranian Pregnancies

Reza Heidari; Mostafa Akbariqomi; Elaheh Motevaseli; Mir Davood Omrani; Hamid Kooshki; Ahmad Reza Shamshiri; Shilan Shafei; Moloud Absalan; Mohammad Ali Mazlomi; Soraya Saleh Gargari; Gholamreza Tavoosidana

Performance and Predictive Value of First Trimester Screening Markers for Down Syndrome in Iranian Pregnancies

Gholamreza Tavoosidana

Abstract

Objective: To investigate the performance of first trimester Down syndrome (DS) screening markers in Iranian pregnancies.Although sonographic and serum markers are currently recommended for the first trimester screening of Down syndrome, the screening performance of the markers depends on the race and ethnicity.
Materials and methods: A retrospective case-control study using first trimester screening results recorded with the prenatal diagnostic multi-centers in Iran. A total of 6,384 pregnant women were examined from March 2012 to February 2017. Totally 100 Down syndrome cases and 266 matched controls were selected and the maternal characteristics, sonographic and biochemical screening data were collected. Statistical analysis was performed using logistic regression and descriptive statistics. A decision tree model was designed using the chi-squared automatic interaction detection method based on serum markers.
Results: For screening of DS pregnancies, PAPP-A (cut-off 0.795 MoM) yielded the highest sensitivity (86%) and NB marker presented highest specificity (96.24%). combination of the biochemical markers PAPP-A and β-hCG (cut-off: 1.55 MoM) showed the highest sensitivity over other combined markers. The decision-tree model based on serum markers improved (91% DR For a 5% FPR) first trimester screening performance.
Conclusion: The novel decision-tree model base on serum markers revealed a better predictive value to achieve high sensitivity and specificity of first trimester Down syndrome screening in Iranian population.

References

Benn P, Borrell A, Chiu RW, Cuckle H, Dugoff L, Faas B, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2015;35(8):725-34.

Niemimaa M, Suonpaa M, Perheentupa A, Seppala M, Heinonen S, Laitinen P, et al. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland. Eur J Hum Genet 2001;9(6):404-8.

Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353(19):2001-11.

Egan JFX, Smith K, Timms D, Bolnick JM, Campbell WA, Benn PA. Demographic differences in Down syndrome livebirths in the US from 1989 to 2006. Prenatal Diagnosis 2011;31(4):389-94.

de Wert G, Dondorp W, Bianchi DW. Fetal therapy for Down syndrome: an ethical exploration. Prenatal Diagnosis 2017;37(3):222-8.

Freeman SB, Bean LH, Allen EG, Tinker SW, Locke AE, Druschel C, et al. Ethnicity, sex, and the incidence of congenital heart defects: a report from the National Down Syndrome Project. Genetics in medicine : official journal of the American College of Medical Genetics 2008;10(3):173-80.

Tongsong T, Tongprasert F, Srisupundit K, Luewan S, Traisrisilp K. Cardio-STIC (spatio-temporal image correlation) as genetic ultrasound of fetal Down syndrome. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2015;28(16):1943-9.

Poursadegh Zonouzi AA, Ahangari N, Rajai S, Poursadegh Zonouzi A, Akbarzadeh Laleh M, Nejatizadeh A. Congenital heart defects among Down syndrome patients: a clinical profiling. Journal of Public Health 2016;24(1):57-63.

Alldred SK, Takwoingi Y, Guo B, Pennant M, Deeks JJ, Neilson JP, et al. First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening. The Cochrane database of systematic reviews. 2017;3:Cd012600.

ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstetrics and gynecology 2007;109(1):217-27.

Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn 1987;7(9):623-30.

Bersinger NA, Brizot ML, Johnson A, Snijders RJ, Abbott J, Schneider H, et al. First trimester maternal serum pregnancy-associated plasma protein A and pregnancy-specific beta 1-glycoprotein in fetal trisomies. Br J Obstet Gynaecol 1994;101(11):970-4.

Haddow JE, Palomaki GE, Knight GJ, Williams J, Miller WA, Johnson A. Screening of Maternal Serum for Fetal Down's Syndrome in the First Trimester. New England Journal of Medicine 1998;338(14):955-62.

Berktold L, von Kaisenberg CS, Hillemanns P, Vaske B, Schmidt P. Analysis of the impact of PAPP-A, free beta-hCG and nuchal translucency thickness on the advanced first trimester screening. Archives of gynecology and obstetrics 2013;287(3):413-20.

Nicolaides KH, Snijders RJ, Gosden CM, Berry C, Campbell S. Ultrasonographically detectable markers of fetal chromosomal abnormalities. Lancet 1992;340(8821):704-7.

Ville Y, Lalondrelle C, Doumerc S, Daffos F, Frydman R, Oury JF, et al. First-trimester diagnosis of nuchal anomalies: significance and fetal outcome. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 1992;2(5):314-6.

Kagan KO, Avgidou K, Molina FS, Gajewska K, Nicolaides KH. Relation between increased fetal nuchal translucency thickness and chromosomal defects. Obstetrics and gynecology 2006;107(1):6-10.

Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001;358(9294):1665-7.

Sainz JA, Serrano R, Borrero C, Turmo E. First trimester contingent test as a screening method for Down's syndrome. A prospective study in the general population. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet 2012;25(11):2221-4.

Quattrocchi T, Baviera G, Pochiero T, Basile F, Rizzo L, Santamaria A, et al. Maternal Serum PAPP-A as an Early Marker of Obstetric Complications? Fetal Diagnosis and Therapy 2015;37(1):33-6.

Leung TY, Spencer K, Leung TN, Fung TY, Lau TK. Higher median levels of free beta-hCG and PAPP-A in the first trimester of pregnancy in a Chinese ethnic group. Implication for first trimester combined screening for Down's syndrome in the Chinese population. Fetal Diagn Ther 2006;21(1):140-3.

Manotaya S, Zitzler J, Li X, Wibowo N, Pham TM, Kang MS, et al. Effect of ethnicity on first trimester biomarkers for combined trisomy 21 screening: results from a multicenter study in six Asian countries. Prenat Diagn 2015;35(8):735-40.

Unal I. Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach. Computational and Mathematical Methods in Medicine 2017;2017:14.

De Souza E, Alberman E, Morris JK. Down syndrome and paternal age, a new analysis of case-control data collected in the 1960s. Am J Med Genet A 2009;149a(6):1205-8.

Fisch H, Hyun G, Golden R, Hensle TW, Olsson CA, Liberson GL. The influence of paternal age on down syndrome. J Urol 2003;169(6):2275-8.

Mazzoni GT, Jr., Cabral AC, de Lima Faria MM, Castro MJ, de Carvalho Pires M, Johnson DS, et al. Ultrasound evaluation of the fetal nasal bone: what is the most appropriate first-trimester cut-off point for aneuploidy screening? Archives of gynecology and obstetrics 2012;285(5):1263-70.

Has R, Kalelioglu I, Yuksel A, Ibrahimoglu L, Ermis H, Yildirim A. Fetal nasal bone assessment in first trimester down syndrome screening Fetal Diagn Ther. 2008;24(1):61-6.

Cicero S, Rembouskos G, Vandecruys H, Hogg M, Nicolaides KH. Likelihood ratio for trisomy 21 in fetuses with absent nasal bone at the 11-14-week scan. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2004;23(3):218-23.

Poureisa M, Daghighi MH, Mazaheri Khameneh R, Salehi Majd S. Fetal Nasal Bone Status In Iranian Women Undergoing First-Trimester Screening For Trisomy 21: A Review and an Observational Study. Iranian Journal of Radiology 2015;12(4):e11905.

Zoppi MA, Ibba RM, Axiana C, Floris M, Manca F, Monni G. Absence of fetal nasal bone and aneuploidies at first-trimester nuchal translucency screening in unselected pregnancies. Prenat Diagn 2003;23(6):496-500.

Driscoll DA, Gross SJ. First trimester diagnosis and screening for fetal aneuploidy. Genetics in medicine : official journal of the American College of Medical Genetics 2008;10(1):73-5.

Thilaganathan B, Khare M, Williams B, Wathen NC. Influence of ethnic origin on nuchal translucency screening for Down's syndrome. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 1998;12(2):112-4.

Shaw SW, Hsiao CH, Chen CY, Ren Y, Tian F, Tsai C, et al. Noninvasive prenatal testing for whole fetal chromosomal aneuploidies: a multicenter prospective cohort trial in Taiwan. Fetal Diagn Ther 2014;35(1):13-7.

Wiechec M, Knafel A, Nocun A, Matyszkiewicz A, Juszczak M, Wiercinska E, et al. How Effective Is First-Trimester Screening for Trisomy 21 Based on Ultrasound Only? Fetal Diagn Ther 2016;39(2):105-12.

Christiansen M, Ekelund CK, Petersen OB, Hyett J, Eastwood N, Ball S, et al. Nuchal translucency distributions for different chromosomal anomalies in a large unselected population cohort. Prenatal Diagnosis 2016;36(1):49-55.

Dane B, Dane C, Cetin A, Kiray M, Sivri D, Yayla M. Pregnancy outcome in fetuses with increased nuchal translucency. J Perinatol 2008;28(6):400-4.

Pummara P, Tongsong T, Wanapirak C, Sirichotiyakul S, Luewan S. Association of first-trimester pregnancy-associated plasma protein A levels and idiopathic preterm delivery: A population-based screening study. Taiwanese Journal of Obstetrics and Gynecology 2016;55(1):72-5.

Tørring N. First trimester combined screening – focus on early biochemistry. Scandinavian Journal of Clinical and Laboratory Investigation 2016;76(6):435-47.

Benn P. Improved antenatal screening for Down's syndrome. Lancet 2003;361(9360):794-5.

Lee FK, Chen LC, Cheong ML, Chou CY, Tsai MS. First trimester combined test for Down syndrome screening in unselected pregnancies - a report of a 13-year experience. Taiwanese journal of obstetrics & gynecology 2013;52(4):523-6.

Sahota DS, Leung TY, Chan LW, Law LW, Fung TY, Chen M, et al. Comparison of first-trimester contingent screening strategies for Down syndrome. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology 2010;35(3):286-91.

Files	XML PDF (518KB)
Issue	Vol 12, No 3 (September 2018)
Section	Original Articles
Keywords
Down Syndrome First Trimester Screening Serum Marker Sonographic Markers

Rights and permissions
	This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Heidari R, Akbariqomi M, Motevaseli E, Omrani MD, Kooshki H, Shamshiri AR, Shafei S, Absalan M, Mazlomi MA, Saleh Gargari S, Tavoosidana G. Performance and Predictive Value of First Trimester Screening Markers for Down Syndrome in Iranian Pregnancies. J Family Reprod Health. 2018;12(3):121-128.

Download Citation